Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Ticagrelor to Clopidogrel in ACS Patients (OPTIMA-5)
NCT04116931Phase 4Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in acute coronary syndrome (ACS) (4 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Platelet inhibition measured by Light Transmittance Aggregometry method (LTA) at 72 hours. Status: unknown.
02
Drugs
clopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04116931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116931.